Dainippon Sumitomo To Put Muscles Behind Lurasidone
This article was originally published in PharmAsia News
Dainippon Sumitomo Pharma President Masayo Tada said the company aims to bring in ¥70 billion in sales for its antipsychotic drug Latuda (lurasione) in 2014
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.